Zydus Lifesciences Limited (ZYDUSLIFE) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹1,215.9 (+1.37% day change)
Key ratios
- P/E ratio
- 24.27
- P/B ratio
- 3.23
- ROE (%)
- 18.59
- ROCE (%)
- 15.77
- Debt/Equity
- 0.46
- Dividend yield (%)
- 1.26
- Market cap (₹ Cr)
- 121,286.51
Forensic checks
Piotroski F-Score: 4/9 · Altman Z-Score: 7.55 · Beneish M-Score: -2.17
InvestSights quality score
79.4/100 — High Quality (descriptive data-driven composite; not a recommendation)
Management guidance track record
- Annual energy consumption: guided 32.57lakh GJ, delivered 31.7lakh GJ (FY25) — exceeded guidance
- EBITDA margin: guided 26%, delivered 31.2% (FY26) — exceeded guidance
Latest earnings call (Q2 FY27)
AI summary: The central signal is that Zydus is deliberately absorbing substantial near-term investment to shift its US business from generics toward specialty, rare diseases and biologics, while still maintaining FY27 EBITDA margin guidance of 24%. Saroglitazar is the clearest test of this strategy: management expects commercial expenditure of around $100 million every year, plans a…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.